发明名称 |
5-lipoxygenase-activating protein inhibitor |
摘要 |
Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases. |
申请公布号 |
US8772495(B2) |
申请公布日期 |
2014.07.08 |
申请号 |
US200912471106 |
申请日期 |
2009.05.22 |
申请人 |
Panmira Pharmaceuticals, LLC |
发明人 |
Schaab Kevin Murray;Stock Nicholas Simon |
分类号 |
C07D401/14;A61K31/444 |
主分类号 |
C07D401/14 |
代理机构 |
Wilson, Sonsini, Goodrich & Rosati |
代理人 |
Wilson, Sonsini, Goodrich & Rosati |
主权项 |
1. A crystalline polymorphic Form C of sodium 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethylpropionate: having an X-ray powder diffraction spectrum with peaks comprising the 2-theta values listed below, obtained with a diffractometer using copper Kα-radiation;Angle 2-Theta°Intensity %15.642.716.643.317.26917.842.618.449.219.110019.840.520.891.623.147.823.859.2. |
地址 |
San Diego CA US |